Hengrui Medicine announced that the company is in the process of issuing overseas listed foreign shares (H shares) and listing them on the main board of the Hong Kong Stock Exchange. The total number of H shares offered globally is 225 million shares, of which 48.2718 million shares are offered to the public in Hong Kong and 176 million shares are offered internationally. Based on the offering price of HK$44.05 per H share, the net proceeds from the global offering are estimated to be approximately HK$9.747 billion. The Chinese abbreviation of the H-share stock is "Hengrui Medicine", the English abbreviation is "HENGRUI PHARMA", and the stock code is "1276". After the completion of this offering, the total number of shares of the company will become 6.637 billion shares, of which H-share shareholders will hold 3.89% of the shares.